clinical trial · NCT07079475
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Dizal (Jiangsu) Pharmaceutical Co., Ltd.·phase2·recruiting·n = 200
Non-Small Cell Lung CancerDZD6008SunvozertinibOsimertinib
brief summary
This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment
started
Jul 31, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2029
last updated
Dec 24, 2025
official title
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combined With Sunvozertinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN8)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol